Abstract
So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Current Pharmaceutical Design
Title:Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Volume: 20 Issue: 15
Author(s): Emily C. Vogler and Jorge Busciglio
Affiliation:
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Abstract: So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Export Options
About this article
Cite this article as:
Vogler C. Emily and Busciglio Jorge, Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990510
DOI https://dx.doi.org/10.2174/13816128113199990510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design What Can Neuroscience Tell Us About the Potential of Psychedelics in Healthcare? How the Neurophenomenology of Psychedelics Research Could Help us to Flourish Throughout Our Lives, as Well as to Enhance Our Dying
Current Drug Abuse Reviews tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Fluorescent Dyes for Bio-Applications in the Patent Literature
Recent Patents on Materials Science Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design Lexical Characterisation of Bio-Ontologies by the Inspection of Regularities in Labels
Current Bioinformatics Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry 2, 5-Disubstituted Phthalimides: Design, Synthesis and Anticonvulsant Activity in scPTZ and MES Models
Current Computer-Aided Drug Design Studies on Target Genes of General Anesthetics
Current Drug Targets In Vivo MRI in Different Models of Experimental Epilepsy
Current Drug Targets R-Type Voltage-Gated Ca<sup>2+</sup> Channels in Cardiac and Neuronal Rhythmogenesis
Current Molecular Pharmacology Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology NMDA Receptors are not Alone: Dynamic Regulation of NMDA Receptor Structure and Function by Neuregulins and Transient Cholesterol-Rich Membrane Domains Leads to Disease-Specific Nuances of Glutamate- Signalling
Current Topics in Medicinal Chemistry Biophysical Modeling and Associated Signal Modeling in Functional Magnetic Resonance Imaging
Neuroscience and Biomedical Engineering (Discontinued)